16 September 2026 editorial review · Item
Insulin glargine U100 (Lantus + biosimilars): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Insulin glargine U100 (Lantus + biosimilars)
Scope and findings:
- Read live FDA biosimilar record and primary payer shortage bulletin. Added missed2026 Langlara approval and regional SoloStar supply caveat. Historical basal PK/comparative efficacy and every-market supply not freshly established.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.